Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes
Posted inDiabetes & Endocrinology news

Pre-Meal Whey Protein: A Targeted Nutritional Intervention to Mitigate Postprandial Hyperglycemia in Gestational Diabetes

A randomized controlled trial demonstrates that a 20g whey protein pre-load 30 minutes before breakfast significantly reduces postprandial glucose excursions and glycemic variability in women with gestational diabetes throughout the third trimester, offering a promising non-pharmacological management strategy.
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
Posted inCardiology Diabetes & Endocrinology news

Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial

The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of target-lesion failure and revascularization at 12 months.
Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF
Posted inCardiology Diabetes & Endocrinology news

Sex-Specific Phenotypes and the Evolving Landscape of Aldose Reductase Inhibition in Diabetic Cardiomyopathy: Insights from ARISE-HF

This analysis of the Phase 3 ARISE-HF trial explores sex differences in diabetic cardiomyopathy (DbCM) and the efficacy of AT-001. While women presented with worse exercise capacity and health status at baseline, the novel aldose reductase inhibitor AT-001 showed consistent safety and efficacy across both sexes.
Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial
Posted inDiabetes & Endocrinology news

Metformin Mitigates Betamethasone-Induced Glycemic Dysregulation and Reduces Neonatal Hypoglycemia: Insights from a Randomized Clinical Trial

A multicenter randomized trial demonstrates that prophylactic metformin administration after antenatal betamethasone significantly improves maternal glycemic control and halves the risk of neonatal hypoglycemia in preterm infants, offering a safe intervention for a long-standing clinical challenge.
Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism
Posted inDiabetes & Endocrinology Gastroenterology news

Pemvidutide Demonstrates Robust MASH Resolution in IMPACT Phase 2b Trial: Clinical Implications of Dual GLP-1/Glucagon Agonism

The 24-week results of the IMPACT trial show that pemvidutide significantly improves MASH resolution without worsening fibrosis. While fibrosis improvement did not reach significance at this early time point, the drug's safety profile and metabolic efficacy mark a significant step forward in hepatology.
High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial
Posted inDiabetes & Endocrinology news Pediatrics

High-Dose Oral Insulin Fails to Prevent Islet Autoimmunity: Primary Results from the POInT Randomized Trial

The POInT trial demonstrated that high-dose daily oral insulin does not prevent islet autoantibodies in infants at high genetic risk for type 1 diabetes. Despite its safety, the primary endpoint was not met, though genotype-specific interactions suggest a need for more personalized prevention strategies.
Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes
Posted inDiabetes & Endocrinology Internal Medicine news

Video Consultations for Insulin Pump-Treated Type 1 Diabetes: Non-Inferior Glycemic Control with Nuanced Patient Outcomes

A 52-week RCT demonstrates that video consultations achieve comparable Time in Range (TiR) to physical visits for T1D patients on insulin pumps. While the intervention improved HbA1c and treatment satisfaction, it was associated with an inferior impact on patient quality of life.